M&As this week: Johnson & Johnson, Acelity, CDH Genetech

15 June 2018 (Last Updated July 27th, 2018 07:52)

Johnson & Johnson (J&J) has accepted a $2.1bn binding offer from Platinum Equity to acquire its blood glucose monitoring systems manufacturing subsidiary Lifescan Inc.

Johnson & Johnson (J&J) has accepted a $2.1bn binding offer from Platinum Equity to acquire its blood glucose monitoring systems manufacturing subsidiary Lifescan Inc.

LifeScan will operate as a standalone business, upon completion of the transaction in the fourth quarter of this year. J&J will work closely with Platinum Equity and ensure a seamless transition for its patients.

Based in the US, J&J is engaged in the development, manufacture and distribution of healthcare products, while Platinum Equity, also based in the US, is an investment firm.

Acelity has entered an agreement to purchase Crawford Healthcare and its assets for an undisclosed sum.

The acquisition includes Crawford’s commercial products, research and development (R&D) capabilities and manufacturing operations based in Cheshire, UK.

Based in the US, Acelity develops wound therapeutic products, while Crawford Healthcare is a UK-based provider of skin and wound care products.

The transaction will enable the acquirer company to expand its portfolio of advanced wound dressings (AWD) and strengthen its position in the wound healing market.

CDH Genetech has signed an agreement to acquire Sirtex for A$1.9bn.

“The transaction will enable the acquirer company to expand its portfolio of advanced wound dressings (AWD) and strengthen its position in the wound healing market.”

Sirtex declined a previous takeover bid offer from US-based company Varian Medical.

Sirtex shareholders will receive A$33.60 ($39.52) in cash for each share held in the company.

Based in Australia, Sirtex is a developer of liver cancer treatment, while CDH is a China-based fund management company. China Grand Pharma is a China-based developer of pharmaceutical preparations and medical devices.

Esco Group has entered an agreement to purchase the remaining shares in AT Medical UAB for an undisclosed sum.

AT Medical UAB will be operated as Esco Medical Technologies UAB within Esco Group’s life science ecosystem, upon completion of the transaction this month.

Based in Singapore, Esco Group is a life science company, while AT Medical UAB is a medical devices manufacturer based in Lithuania.

The transaction will enable the acquirer company to enhance its product development.